MedTrace Logo

Prepulse Inhibition (PPI) of Startle Reflex in Schizophrenia Patients Related to Type of Treatment and Illness Duration

NCT02484521 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2020-02-13

No results posted yet for this study

Summary

PPI is an objective measure to assess pre-attentive processes that have already been tested before in the case of schizophrenia. The investigators aim to assess through this instrument two main characteristics, that the investigators assume are of relevance which are the duration of illness and the type of pharmaceutical treatment, patients receive.

The investigators believe these two main characteristics are critical to the ability of the patients in improvement of their PPI response to startle reflex.

Conditions

Interventions

DEVICE

PPI monitoring device protocol

The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.

OTHER

Questionnaires

Group of patients diagnosed with schizophrenia would be interviewed using well validated questionnaires. Questionnaires what would be used are: 1. GAF- Global assessment of functioning 2. PANSS- Positive and negative syndrome scale 3. SANS- Scale for the Assessment of Negative Symptoms 4. The Calgary Depression Scale for schizophrenia 5. Demographic Questionnaire 6. Hamilton Anxiety scale

Sponsors & Collaborators

  • HaEmek Medical Center, Israel

    lead OTHER

Principal Investigators

  • elad kurante, MD · haemek MC

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02484521 on ClinicalTrials.gov